- Home
- RNAZ vs NCNA Comparison
RNAZ vs NCNA Comparison
Compare RNAZ & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- NCNA
- Stock Information
- Founded
- RNAZ 2016
- NCNA 1997
- Country
- RNAZ United States
- NCNA United Kingdom
- Employees
- RNAZ N/A
- NCNA N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- NCNA Health Care
- Exchange
- RNAZ Nasdaq
- NCNA Nasdaq
- Market Cap
- RNAZ 4.9M
- NCNA 4.4M
- IPO Year
- RNAZ 2021
- NCNA 2017
- Fundamental
- Price
- RNAZ $3.84
- NCNA $1.28
- Analyst Decision
- RNAZ Strong Buy
- NCNA Buy
- Analyst Count
- RNAZ 1
- NCNA 2
- Target Price
- RNAZ $99.00
- NCNA $25.00
- AVG Volume (30 Days)
- RNAZ 30.4K
- NCNA 99.0K
- Earning Date
- RNAZ 11-14-2024
- NCNA 11-25-2024
- Dividend Yield
- RNAZ N/A
- NCNA N/A
- EPS Growth
- RNAZ N/A
- NCNA N/A
- EPS
- RNAZ N/A
- NCNA N/A
- Revenue
- RNAZ N/A
- NCNA N/A
- Revenue This Year
- RNAZ N/A
- NCNA N/A
- Revenue Next Year
- RNAZ $233.33
- NCNA N/A
- P/E Ratio
- RNAZ N/A
- NCNA N/A
- Revenue Growth
- RNAZ N/A
- NCNA N/A
- 52 Week Low
- RNAZ $6.31
- NCNA $1.20
- 52 Week High
- RNAZ $264.00
- NCNA $19.40
- Technical
- Relative Strength Index (RSI)
- RNAZ 23.15
- NCNA 38.62
- Support Level
- RNAZ $6.63
- NCNA $1.23
- Resistance Level
- RNAZ $8.46
- NCNA $1.39
- Average True Range (ATR)
- RNAZ 1.04
- NCNA 0.06
- MACD
- RNAZ -0.25
- NCNA 0.03
- Stochastic Oscillator
- RNAZ 1.65
- NCNA 37.05
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.